Amryt Pharma Share Discussion Threads

[alphabravo321] 14/10/2020 21:09

Between 3 and 5 November separate investor events and calls, you could be forgiven for thinking they are setting this up for good news

[ultrasharp] 14/10/2020 18:27

free stock charts from uk.advfn.com

I see early September's intraday high being retested following a couple of good RNS's within the next 3 weeks.
ATB PAPILLON

[ultrasharp] 14/10/2020 15:44

Just 10 ADS's traded on Nasdaq so far today! 🤣🤣🤣🤣. And I thought listing on Nasdaq was a good idea! How wrong can you be?

I see that the AMYT share price on AIM has fallen today and is now more in line with the equivalent price on Nasdaq. What took it so long?

ATB PAPILLON

[ultrasharp] 14/10/2020 10:37

Q3 results to be issued on bonfire night, November 5th. 🤣

[gnnmartin] 14/10/2020 10:36

Does anyone understand how you will be able to listen to the playback of the conference call on 5 November? The RNS reads like you have to telephone in, which sounds unlikely. I would hope that it would be available on the web.

[ultrasharp] 13/10/2020 17:49

The share price is holding up.

ATB PAPILLON

[diamondstar1] 12/10/2020 20:52

Price on Nasdaq today between 12.01-12.48 today, equivalent to £1.85-1.92.

[bageo] 12/10/2020 16:36

Did have to look carefully and scroll across

A+B (holding + financial instrument)

old 6.13% new 6.12%
Logically somebody (or maybe more than 1 party) must hold the shares relating to this financial instrument - so another holding RNS due?

Shareholding has gone from 2.60% to nothing but economic exposure of UBS is essentially unchanged (0.01% difference)

[digadee] 12/10/2020 13:55

Hi gnamartinI have no idea how you have come to that conclusion, doesnt mean you are wrong though but i pritty much read it how paps explained it.

[gnnmartin] 12/10/2020 12:27

I don't think that's right. I think they have sold 2.6% of the shares, and bought CFDs (or some such) for 2.59%. So a net tiny fall in their holding, though that might be rounding error.

[punter6] 12/10/2020 12:09

That's a £6.3 million investment by UBS,right?

That's a serious investment.

[ultrasharp] 12/10/2020 11:57

It's quite straightforward, Ali. They have increased their holding. From over 6m to over 9m shares. That's 6.12% of AMYT shares.
If you can't understand the RNS look at the Amryt Web site. I did this morning. They hadn't yet updated the major shareholdings following today's RNS. You could see that the latest 6.12% is an increase on the figure quoted on the Web site

ATB PAPILLON

[digadee] 12/10/2020 10:54

Ali, yes looks like they have been adding

[ali47fish] 12/10/2020 10:07

is ubs adding today's rns?

[alphabravo321] 11/10/2020 11:30

I will continue wondering so

[ultrasharp] 10/10/2020 21:59

But Cathal Friel is no longer on the AMYT BoD and has no input into the running and future direction of the company. We're not even sure whether he still holds any AMYT shares since his stake went below a notifiable 3% following last year's RTO. He could have gradually sold them. After all in the period after the RTO there were many very large trades.

ATB PAPILLON

[alphabravo321] 10/10/2020 15:22

No real reason, just the hand of CF in both and similar market segment etc

[bermudashorts] 09/10/2020 18:59

Yep well done chica and agree that there doesn't seem to be any synergy between ORPH and AMYT. I assume Amryt are after approved, revenue generating drugs for rare diseases that will slot into their current sales and marketing infrastructure.

By the way, don't confuse under the radar with boring. Amryt's acquisition of Aegerion was an extraordinary transaction and whilst they are quietly going about their business, over recent months they've taken the company to a £330m market cap, have projected revenue this year of around $170m, have listed on NASDAQ and released the results of the largest ever EB phase III trial. Perhaps not the hype that accompanies other stocks but certainly not boring.

[chica1] 09/10/2020 12:11

Just over 1.25..

I just hope Amryt doesn't buy Open Orphan.It will never happen they are 2 different businesses.

[ultrasharp] 09/10/2020 11:56

Well done chica1 on your success with ORPH. You have almost had a 5 bagger
By the way what price did you get when you sold your AMYT?

PS Don't forget AMYT has gone from 73p to the current 207p in 13 months. Thats almost a 3 bagger for me. Hardly boring!

ATB PAPILLON

[chica1] 09/10/2020 11:49

I hope not Amryt is so boring.
I actually sold all my stock in Amryt because the samples we got of Episalvan were useless.
Someone mentioned Open Orphan on here and after a little research I bought it at 5.4 pence.

Open Orphan business is vaccines testing.They are the only company in the world that can do a Covid Challenge Study.
There will be billions invested in vaccine testing over the next 10 years.

They also have Imutex which has a phase 2 Universal flu vaccine and a Zica vaccine that the Lancet said could be a game changer.(that is either going to be sold or listed on the Nasdaq)
The also have a Database which they inherited from the acquisition of Hvivo that has information on all virology going back to the 1950's and Apple and Google are looking for exclusive right to it.

[digadee] 09/10/2020 10:03

Hey alphaThe thought did cross my mind to be honest but can the current valuation of £160m really be justified. Its all hype on the back of covid vaccine stuff???

[punter6] 09/10/2020 09:33

Why would that happen Alpa?

(Not being smart now,just curious)

[alphabravo321] 09/10/2020 07:40

I wonder if Open Orphan could be a potential target of Amryt, all share deal maybe

[richpassi] 09/10/2020 06:46

Looking to be very busy :)